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Abstract
Purpose The aim of this study was to determine the relation-
ship between [18]-2-fluoro-2-deoxy-D-glucose (FDG) uptake
and excision repair cross-complementation group 1 (ERCC-1)
expression and to evaluate the prognostic effect of these two
factors in resectable non-small cell lung cancer (NSCLC)
patients.
Methods We retrospectively reviewed 212 patients with re-
sectable NSCLC who underwent FDG positron emission
tomography/computed tomography (PET/CT) scan for cancer
staging and ERCC-1 expression analysis between January
2008 to December 2011. All patients were then followed-up
for survival analysis. Semiquantitative evaluation of ERCC-1
was performed with the H-scoring system and was correlated
with maximum standardized uptake value (SUVmax) of
NSCLC. Univariate andmultivariate analyses were performed
to evaluate for FDG uptake and ERCC-1 expression
predicting overall survival.
Results In 212 patients (139 male, median age 68±9.11), 112
patients had ERCC-positive tumors and 100 patients had
ERCC-negative tumors. There was no significant difference
in SUVmax between ERCC-1-positive tumors (8.02±5.40)
and ERCC-1-negative tumors (7.57±6.56, p=0.584). All pa-
tients were followed-up for a median of 40.5 months (95 %
confidence interval [CI], 38.5–42.2 months). Univariate
analysis and multivariate analysis for all patients showed that
both ERCC-1 expression (hazard ratio [HR], 2.78; 95 % CI,
1.20–6.47) and FDG uptake (HR, 4.50; 95 % CI, 2.07–9.77)
independently predicted overall survival.
Conclusions We have found no statistical correlation between
FDG uptake and ERCC-1 expression in NSCLC. However,
both higher FDG uptake and positive ERCC-1 expression are
independent predictive markers of prognosis, suggesting that
both should be obtained during patient workup.
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Introduction
Lung cancer is the leading cause of death in developed coun-
tries. Nearly 85% of lung cancer cases are non-small cell lung
cancer (NSCLC), where early diagnosis and effective therapy
are the two main clinical factors affecting patient prognosis.
Although significant therapeutic advances have been
achieved, poor prognosis and short survival time have yet to
be resolved. Despite undergoing complete resection of
NSCLC, 5-year survival rates for pathological stage IA is
66 %, and stage IIIA patients have relatively lower 5-year
survival rates of 23 % compared with other tumors [1].
Platinum-based chemotherapy is one of the most routinely
used treatment modalities for NSCLC. Platinum-based adju-
vant chemotherapy is usually recommended after surgical
resection for patients with good performance status and
completely resected lesions [2]. However, due to the low
response rates of 25–35 % in treatment-naive NSCLC pa-
tients, recent studies have focused on elucidating molecular
markers that predict response to conventional platinum-based
chemotherapy [3–9].
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Excision repair cross-complementation group 1 (ERCC-1)/
xeroderma pigmentosum group F (XPF) protein complex
plays key roles in several DNA repair pathways, particularly
in those involved in the repair of ultraviolet-induced lesions
and intrastrand or interstrand cross links [10]. Clinically,
this protein is known to be associated with platinum-
based chemotherapy resistance in many cancers, includ-
ing NSCLC [11–13]. Previous studies have shown that
NSCLC patients on platinum-based chemotherapy with
increased ERCC-1 expression have lower survival com-
pared with ERCC-1-negative patients [14]. However,
because ERCC-1 expression within primary lesions and
metastases can be heterogenous [15], and invasive pro-
cedures are needed for adequate amounts of specimen
for immunohistochemistry, correlation between ERCC-1
expression with non-invasive metabolic imaging may be
beneficial in determining therapeutic strategy.
[18]-2-Fluoro-2-deoxy-D-glucose positron emission tomog-
raphy (FDG PET) is now established in the routine evaluation
of lung cancer staging, and has the unique ability to provide
metabolic information for each tumor’s glycolytic metabolic
rate. When combined with anatomical imaging techniques,
FDG PET has been shown to correlate well with tumor
grading and after-treatment prognosis [16]. Previous studies
have shown that ERCC-1 expression was correlated with
GLUT-1 expression and insulin level, which is a known factor
for FDG uptake in tumors [17, 18]. This suggests that there
may be a potential correlation between ERCC-1 and FDG
uptake in tumors. However, there are limited data correlating
FDG uptake with chemotherapy-resistant tumor markers such
as ERCC-1 in NSCLC. There have been only two studies
evaluating the correlation between ERCC-1 expression and
FDG uptake in NSCLC, and both are conflicting and have a
small patient population [18, 19]. In addition, both studies did
not evaluate the prognostic effect of ERCC-1 expression and
FDG uptake. The purpose of this study was to determine the
relationship between FDG uptake and ERCC-1 expression
and to evaluate prognostic effect of these two factors in
resectable NSCLC patients.
Material and Methods
This retrospective study was approved by our institutional
review board. We retrospectively reviewed 212 patients with
resectable NSCLC (139 men; mean age, 68 years old; range,
39–87 years) who underwent FDG PET/CT scan for cancer
staging between January 2008 to December 2011 in the our
medical center. TNM staging was determined according to the
seventh AJCC staging guidelines and contrast-enhanced CT
was obtained before surgery. Pathological diagnosis was ob-
tained by surgery in all 212 patients. We chose ERCC-1 as a
surrogate of chemoresistance protein, and H-scoring system
was performed by standard immunostaining method in the
primary lung cancer tissue by semiquantitative evaluation. To
calculate H-score, the staining intensity (graded on a scale of
0–3) and the percentage of positive tumor nuclei proportion (0
if 0 %, 0.1 if 1–9 %, 0.5 if 10–49 %, and 1.0 if 50 % or more)
were multiplied for each case, as previous studies have de-
scribed [6]. The median value of H-scores of all patients was
chosen as the cutoff value for separating ERCC-1-positive
tumors from ERCC-1 negative tumors. Platinum-based adju-
vant chemotherapy was indicated in patients higher than stage
IB, according to the NCCN criteria for NSCLC patients. This
retrospective study was approved by our institutional review
board.
Whole-body PET/CT was performed using a Discovery
600 and Discovery PET/CT 600 (General Electric Medical
Systems, Milwaukee, WI). All patients fasted for at least 6 h
and blood glucose concentration was confirmed to be less than
130 mg/dl before the injection of 18F-FDG. Approximately
5.5 MBq of 18F-FDG per kilogram of body weight were
administered intravenously. PET/CT scanning was performed
from the skull base to the mid-thigh 60 min after injection.
Spiral CT was performed using the following parameters: a
scout view at 10 mA and 120 kVp, followed by a spiral CT
scan with a 0.8-s rotation time, 60 mA, 120 kVP, 3.75-mm
section thickness, 1.25-mm collimation and 27.5-mm table
feed per rotation with arms raised. PET image acquisition
followed CT scanning, 2 min per bed position of 15.7 cm in
three-dimensional acquisition mode. PET, PET/CT and CT
images were analyzed using a dedicated Advanced Worksta-
tion (General Electric Medical Systems). Semiquantitative
analysis of PET images was performed by an experienced
nuclear medicine physician. Briefly, a region of interest
(ROI) of primary lung tumor was drawn, and the maximum
standardized uptake values (SUVmax) was recorded. Receiv-
er operation characteristic (ROC) curve analysis was per-
formed to determine the optimal cutoff value of SUVmax that
would best predict overall survival in patients.
For statistical analysis, chi-squared analysis was per-
formed to correlate between ERCC-1 expression with clin-
ical factors such as age, gender, histologic subtype, TNM
stage, and chemotherapy status. Independent samples t-test
was performed to determine the correlation between FDG
uptake with ERCC-1 expression. Sub-analysis according to
histologic subtype for ERCC-1 with FDG uptake was also
performed as squamous cell carcinoma is well known to
have higher FDG uptake compared with adenocarcinoma.
Univariate survival analysis was performed for clinical
factors and FDG uptake for overall survival. Multivariate
analysis was performed for statistically significant factors
in univariate analysis. All statistical computations were
performed using SPSS 20.0 software (SPSS, Chicago, IL,
USA) and a pvalue <0.05 was considered statistically
significant.
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Results
In 212 patients, 112 patients had ERCC-positive tumor
and 100 patients had ERCC-negative tumor by H-scoring
system. Pathologic histologic subtype was 147 patients
with adenocarcinoma and 65 patients with squamous-cell
carcinoma. There was no significant difference between
ERCC-1 expression from patient characteristics such as
age, gender, initial tumor stage, or platinum-based adju-
vant chemotherapy (Table 1). Only NSCLC histologic
subtype was correlated with ERCC-1 expression, as pa-
tients with squamous cell carcinoma tended to be ERCC-
1-positive tumors (46/65), and adenocarcinoma pathology
patients tended to have ERCC-1-negative tumors (81/147,
p<0.001). There was no significant difference in SUVmax
of from ERCC-1-positive tumors (8.02±5.40, mean ±
standard deviation) and ERCC-1-negative tumors (7.57±
6.56, p=0.584) (Table 2). In subgroup analysis, there was
no difference in FDG uptake between ERCC-1-positive
and -negative groups in adenocarcinoma (p=0.134) and
squamous-cell carcinoma (p=0.763).
All patients were followed-up for overall survival analysis,
and median follow up duration was 40.5 months (95 % con-
fidence interval [CI], 38.5–42.2 months) and 31 patients
(14.6 %) died during the duration of this study. ROC analysis
showed that FDG uptake that best predicted overall survival
with highest sensitivity was SUVmax 8.1 (sensitivity, 71 %;
area under the curve [AUC], 0.699; p<0.001). When patients
were divided into two groups according to the cutoff value,
there were 78 patients (37 %) in the positive FDG uptake
group and 134 patients (63 %) in the negative FDG uptake
group. The SUVmax of primary lung tumor in the negative
FDG uptake group was 4.11±2.20 (mean ± standard devia-
tion), and 14.17±4.93 in the positive FDG uptake group. In
the entire patient group, ERCC-1-positive patients had
significantly shorter overall survival (OS) than ERCC-1-
negative patients (hazard ratio [HR], 3.36; 95 % CI,
1.66–6.79; Table 3), and average survival was 65 months
for ERCC-1-negative patients compared with 54 months
for ERCC-1-positive patients (p=0.003, Fig. 1a). FDG-
positive patients had significantly shorter OS than FDG-
negative patients (50 months vs 66 months; HR, 5.05;
95 % CI, 2.38–10.70; Fig. 1b). ERCC-1 expression has
been correlated with poorer prognosis in patients under-
going platin-based chemotherapy, so subanalysis of pa-
tient survival was performed for these patients. A total
of 82 patients (38.7 %) underwent chemotherapy, and
45 of these patients (54.9 %) were ERCC-1 positive,
and 37 patients (45.1 %) were ERCC-1 negative. There
was no correlation between ERCC-1 expression (p=
0.055) and FDG uptake (p=0.974) in predicting overall
survival in these patients (Fig. 1c and d). Finally,
Table 1 Characteristics of the
patients Characteristic All
patients
(n=212)
Patients with
ERCC-1-
positive
tumors (n=112)
Patients with
ERCC-1-
negative
tumors (n=100)
p value
Age 68±9.11 68±9.00 67±8.96 0.771
Gender, n (%) 0.652
Male 139 (66) 75 (67) 64 (64)
Female 73 (34) 37 (33) 36 (36)
Histologic type, n (%) <0.001
Squamous-cell carcinoma 65 (31) 46 (41) 19 (19)
Adenocarcinoma 147 (69) 66 (59) 81 (81)
Pathological TNM stage, n (%) 0.837
Stage I 121 (57) 62 (55) 59 (59)
Stage II 51 (24) 29 (26) 22 (22)
Stage III 40 (19) 21 (19) 19 (19)
Tumor, n (%) 0.554
T1 87 (41) 44 (39) 43 (43)
T2 99 (47) 54 (48) 45 (45)
T3 22 (10) 11 (10) 11 (11)
T4 4 (2) 3 (3) 1 (1)
Platinum-based adjuvant chemotherapy, n
(%)
0.637
Yes 82 (39) 45 (40) 37 (37)
No 130 (61) 67 (60) 63 (63)
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multivariate Cox model for all patients showed that both
ERCC-1 expression (HR, 2.78; 95 % CI, 1.20–6.47) and
FDG uptake (HR, 4.50; 95 % CI, 2.07–9.77) indepen-
dently predicted survival for the entire study population.
Other predicting factors were not shown to be statisti-
cally significant (Table 3).
Discussion
We have shown in our study that FDG is not correlated with
ERCC-1 expression in NSCLC. To our knowledge, this is the
largest study assessing the correlation between ERCC-1 ex-
pression and FDG uptake in resectable NSCLC patients.
ERCC-1 is a DNA excision repair protein encoded by the
ERCC-1 gene, involved in the nucleotide excision repair of
damaged DNA. Previous reports have shown that insulin-
induced ERCC-1 mRNA expression via the Ras/ERK-
dependent pathway activates hypoxic signal cascade via
Snail1 pathway, and results in GLUT1 expression in NSCLC
tumors [13, 17]. This implies that tumors expressing ERCC-1
may show high FDG uptake as increased GLUT1 expression
and hypoxic conditions are known to be correlated with
increased FDG uptake. Clinically, correlation of ERCC-1
expression and FDG uptake was not been established in
NSCLC, as only a few retrospective studies with small cohorts
have been reported, and they are conflicting. This may be due
to the small population size and limited data of tumor charac-
ter. One study by Xiao-Yi et al. [19] showed a positive
correlation between SUVmax of ERCC-1-positive cases com-
pared with ERCC-1-negative cases in NSCLC. However,
histologic type of NSCLC was not included in the analysis,
which may be an important variable, as both ERCC-1 and
FDG uptake are significantly higher in squamous cell carci-
noma pathology compared with adenocarcinoma. We have
shown in our larger clinical study that there was no correlation
between ERCC-1 expression and FDG uptake, neither overall
or according to NSCLC subtype. A more precise method to
evaluate for the correlation between FDG uptake with ERCC-
1 expression is animal studies with ex vivo autoradiography
correlated with ERCC-1 immunohistochemical analysis;
however, this is outside the scope of this clinical study.
We have also shown in our study that ERCC-1 and FDG
uptake independently predicted overall survival in resectable
NSCLC patients. Although many clinical factors such as age,
gender, TNM stage, performance status, weight loss and tu-
mor markers show high correlation with NSCLC prognosis [1,
20], there are varying responses to treatment in patients with
resectable NSCLC that highlight the need for better predictive
markers based on tumor metabolism.We have seen in our data
that positive ERCC-1 expression was correlated with poorer
survival. This result contradicts a major study, which has
shown that negative ERCC-1 expression was correlated with
poorer survival in patient groups without treatment [6].
Table 3 Univariate and multivariate analyses of prognostic factors for overall survival in NSCLC
Univariate analysis Multivariate analysis
HR 95 % CI p value HR 95 % CI p value
ERCC-1 expression 3.36 1.66–6.79 0.003a 2.78 1.20–6.47 0.017a
FDG uptake 5.05 2.38–10.70 <0.001a 4.50 2.07–9.77 <0.001a
Age (cutoff, 71 year) 1.87 0.91–3.84 0.078 NS
Gender 0.28 0.13–0.58 0.010a 0.338
TNM stage 0.001a 0.139
Stage I
Stage II 4.39 1.82–10.61
Stage III 3.95 1.56–10.01
Platinum-based CTx 1.96 0.95–4.04 0.057 NS
CTx chemotherapy, HR hazard ratio, CI confidence interval, NS not statistically significant
a Statistically significant
Table 2 Comparison of
SUVmax in primary NSCLC pa-
tients according to ERCC-1
expression
Data are expressed as mean ±
standard deviation
Characteristic Patients with ERCC-1-
positive tumors
Patients with ERCC-1-
negative tumors
p value
Total patients 8.02±5.40 7.57±6.56 0.584
Squamous-cell carcinoma (n=65) 11.30±4.93 14.38±8.00 0.134
Adenocarcinoma (n=147) 5.74±4.47 5.98±5.01 0.763
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However, the correlation between survival and ERCC-1 ex-
pression is still not resolved, as subsequent studies have not
shown a significant correlation between negative ERCC-1
expression with patient survival [9, 21, 22]. We evaluated
the independent survival benefit of both ERCC-1 expression
and FDG uptake in our study, as both markers are suspected to
be correlated with patient survival. We have shown that both
positive ERCC-1 expression and higher FDG uptake is asso-
ciated with poorer survival, and that FDG uptake has a stron-
ger risk factor for poorer survival compared with ERCC-1
(HR 4.5 vs 2.8). This result suggests that both ERCC-1 and
FDG PET/CTcould be beneficial in treatment planning. How-
ever, controlled, prospective studies are needed to fully
evaluate for the possible role of ERCC-1 and FDG PET/CT
in predicting patient prognosis.
ERCC-1 expression analysis has recently been evaluated
due to the DNA repair capability, which can potentially repair
platinum-induced DNA damage. A recent meta-analysis sug-
gested that high ERCC-1 expression was a positive prognostic
factor associated with lower response to platinum-based che-
motherapy in NSCLC, but recent reports have shown no
statistical association between response to therapy with
ERCC-1 expression. FDG uptake has also been extensively
analyzed in predicting therapy response in NSCLC patients,
and although most studies have confirmed that FDG uptake
predicts overall survival, the clinical usefulness of FDG
a
c
b
d
Fig. 1 Kaplan-Meier estimates of the probability of survival. a In the
entire patient group, the ERCC-1-positive patients had significantly
shorter overall survival (OS) than ERCC-1-negative patients (HR, 3.36;
95%CI, 1.66–6.79; p=0.003). b FDG-positive patients (SUVmax cutoff,
8.1) had significantly shorter OS than FDG-negative patients (HR, 5.05;
95 % CI, 2.38–10.70; p<0.001). In patients underwent chemotherapy
group, there was no correlation between c ERCC-1 expression (p=0.055)
and d FDG uptake (p=0.974) in predicting overall survival in these
patients
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uptake in predicting therapy response is not yet established
[23–25]. We have also shown in our study that ERCC-1
expression or FDG uptake predicted survival in platinum-
based chemotherapy patients, but further studies are needed
as our subanalysis study population was relatively small.
In summary, we have found no statistical correlation be-
tween FDG uptake and ERCC-1 expression in NSCLC. How-
ever, both higher FDG uptake and positive ERCC-1 expres-
sion are independent predictive markers of prognosis, sug-
gesting that both should be obtained during patient workup.
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